C ardiovascular disease (CVD) remains a highly prevalent cause of morbidity and mortality, both in the United States and worldwide. In parallel with the development of new and improved therapies for established CVD such as coronary artery disease or heart failure (HF), there has been an increased focus on modification of cardiovascular risk factors for both primary and secondary prevention, reflecting an evolving understanding of CVD as a systemic process with numerous determinants.
Obstructive sleep apnea (OSA) has been associated with many different forms of CVD including hypertension, stroke, HF, coronary artery disease, and atrial fibrillation (AF). 1 Adults with OSA not only have an increased risk of developing comorbid CVD but also have worse outcomes related to CVD. OSA is highly prevalent, estimated to affect 34% of men and 17% of women in the general population 2 and 40% to 60% of patients with CVD. 3, 4 Furthermore, the prevalence is increasing, with these figures representing a 30% increase over the previous 2 decades, 2 likely related to the obesity epidemic as well as an aging population. Despite the clear association between CVD and OSA, randomized trials have failed to demonstrate that treatment of sleep apnea improves hard cardiovascular outcomes in patients with established CVD. 5 Nevertheless, this area remains controversial, as randomized trials performed to date remain limited in number as well as design, highlighting the need for further study. 6 Furthermore, the current literature suggests that the impact of diagnosing and treating OSA varies between specific CVD processes, implying the need for a more sophisticated understanding and nuanced clinical approach to this issue. In this article we review the literature pertaining to OSA in patients with CVD. Additionally, we offer a practical clinical approach to the evaluation and management of known or suspected OSA in patients with CVD consisting of recommendations integrated from several separate societal practice guidelines combined with several of our own suggestions on issues not addressed by current guidelines, based on our own clinical experience and best available literature.
Overview of Sleep Apnea Definition
Sleep apnea is characterized by repetitive episodes of apnea occurring during sleep. An apnea is defined as a cessation of inspiratory airflow lasting 10 seconds or more, while the term hypopnea refers to a reduction in inspiratory airflow (by at least 30%) lasting 10 seconds or more with an associated drop in oxygen saturation or arousal from sleep. 7 The steps required for a successful inspiratory cycle include activation of a signal from the regulatory brainstem center, transmission of the signal via peripheral nerves, activation of respiratory muscles to produce negative intrathoracic pressure, and a patent airway. The mechanism for apneas or hypopneas can be either obstructive, in which airflow cessation results despite inspiratory effort because of blockage within the upper airways, or central, in which both airflow and inspiratory efforts are absent. The term sleep-disordered breathing (SDB) encompasses OSA, central (CSA), and mixed apnea, the latter of which shows absent respiratory effort initially and clear effort with obstruction and the end of mixed apnea. Important risk factors for OSA include obesity, craniofacial or oropharyngeal anatomic abnormalities, male sex, and smoking. 8 During sleep, there is a reduction in tone of the dilator muscles involved in maintaining airway patency. In particular, relaxation of the genioglossus muscle allows the tongue to fall posteriorly within the pharynx, facilitating obstruction in susceptible individuals. 9 Anatomic factors including obesity that result in relative narrowing of the airway lumen increase the likelihood of obstruction. The observation that OSA also affects nonobese patients without identifiable anatomic abnormalities indicates that nonanatomic mechanisms are important as well. Examples of these include ventilatory control instability 10 and reduced sleep arousal threshold. 11 The relative contribution from these processes varies between individual patients, with potential therapeutic implications. A better understanding of the mechanisms underlying OSA could facilitate more personalized therapeutic strategies in the future. CSA results from transient failure of respiratory control centers in the medulla to trigger inspiration. The primary mechanism is thought to be abnormal regulation of the apneic threshold, the partial pressure of CO 2 below which respiration is suppressed, although depending on the underlying cause CSA patients can be either hypercapnic, eucapnic, or hypocapnic. 9 HF is one of the leading causes of CSA, associated in particular with Cheyne-Stokes breathing, which is characterized by cyclic crescendo-decrescendo respiratory efforts and hypocapnia. 12 
Evaluation and Diagnosis
The evaluation for sleep apnea begins with a comprehensive sleep assessment, which includes a thorough clinical history documenting signs or symptoms, such as excessive daytime sleepiness, morning headaches, snoring, witnessed apnea, or difficulty concentrating, a physical examination, and a review of the medical history for relevant comorbidities and other risk factors 13 (Table 1) . Patients with suspected sleep apnea following this assessment should undergo diagnostic testing, the criterion standard of which is polysomnography. Treatment of OSA is generally reserved for those individuals with an apnea-hypopnea index (AHI; the number of apneas and hypopneas observed per hour) ≥5 measured during sleep study in patients with either signs/symptoms of sleep apnea or associated medical conditions (including hypertension, HF, coronary artery disease, significant arrhythmias, and other forms of CVD). Alternatively, an AHI ≥15 is often treated as OSA even in the absence of signs, symptoms, or associated medical conditions. 14 Severity is also determined using the AHI, with 5 to 14 considered mild, 15 to 30 moderate, and >30 severe disease. Significant night-to-night variability of AHI has been observed in studies of consecutive night polysomnography, with 7% to 25% of patients meeting diagnostic criteria for moderate-to-severe OSA the second night despite a negative result the previous evening. 15 Current guidelines therefore recommend repeating polysomnography in patients with a negative initial study when clinical suspicion of OSA remains high. 16 Home sleep apnea testing (HSAT) using a portable monitoring device is a reasonable alternative testing strategy. Several HSAT devices exist, all of which measure heart rate and oximetry with some also measuring nasal pressure, chest and abdominal plethysmography, and/or peripheral arterial tonometry. Compared with polysomnography, the diagnostic accuracy of HSAT is lower and, importantly, varies depending on the population studied and diagnostic criteria used. [17] [18] [19] Despite these caveats, HSAT represents a viable alternative to polysomnography in select circumstances and is recommended for diagnosis of OSA in uncomplicated patients with an increased risk of moderate-to-severe OSA. 7 Given its limited sensitivity and the potential consequences of falsenegative results, negative or nondiagnostic studies should be followed up with polysomnography. Furthermore, patients at risk for central or mixed sleep apnea (significant cardiopulmonary disease, chronic opioid use, history of stroke, or neuromuscular disorders with potential respiratory muscle involvement) or other nonrespiratory sleep disorders requiring evaluation should undergo polysomnography rather than HSAT, 16 because the diagnostic accuracy of the latter for central apneas has not been validated. Because a single night of HSAT is less resource intensive than a single full night of polysomnography, reduced cost has been cited as a potential benefit of increasing HSAT use in diagnosing OSA. Several economic analyses comparing the cost effectiveness of HSAT with full-or split-night polysomnography in adults with suspected moderate to severe OSA instead found full-night polysomnography to be the preferred testing modality. 20, 21 Increased costs related to repeat testing and false-negative HSAT results account for Auto-titrating CPAP (APAP) is another option that offers the advantage of performing titration at home rather than in a sleep laboratory. In APAP, the clinician programs a pressure range, and the level of administered PAP is automatically adjusted throughout the night to the lowest pressure required to maintain upper airway patency using proprietary eventdetection software. Several randomized trials comparing fixed CPAP with APAP showed either no difference or, in some cases, a small advantage of APAP with respect to adherence rate, reduction in AHI, and improvement in sleepiness in cohorts with uncomplicated OSA. 25, 26 Notably, patients with HF, chronic obstructive pulmonary disease or other form of significant lung disease, obesity hypoventilation syndrome, and SDB related to neuromuscular disease were excluded from these studies, and current guidelines recommend against use of APAP for either pressure titration or therapy in these patients. 27 PAP therapy is an efficacious treatment of OSA; however, effectiveness can be limited by patient nonadherence, which is not uncommon and can be caused by a variety of factors. 28 Strategies that may be effective for some patients in improving adherence with therapy include changing the mask interface (superior tolerability of the nasal interface has been suggested), adding humidification to the PAP circuit (effectiveness may be limited to those with nasal congestion), adding a chinstrap to the mask interface (which also appears to reduce air leak and residual AHI), 29 and utilizing an APAP mode. 24 Cognitive behavioral therapy aimed at improving patients' self-efficacy with respect to their health has been shown to increase adherence in several studies. 28 Early assessment and prompt troubleshooting of any problems is extremely important following treatment initiation, because use during the first 2 weeks predicts long-term adherence to therapy. 23 Behavioral therapies for sleep apnea include weight loss, positional therapy, and avoidance of alcohol or other sedating agents (Table 3) . Weight loss reduces the severity of OSA in most overweight patients, with a significant correlation between the magnitude of weight loss and the reduction in AHI. [30] [31] [32] Weight loss can be either medical or surgical. 33 Intensive lifestyle modifications and weight loss may reduce the risk of future cardiovascular events including mortality in overweight/obese patients via mechanisms unrelated to OSA 34, 35 and therefore should be recommended to all such patients with OSA in addition to other therapies. 36 Bariatric surgery is efficacious in terms of both weight loss and reduction in AHI and therefore should be considered in select obese patients with OSA. 37 Although weight loss can reduce AHI, most patients will require some form of additional OSA therapy, because only 10% to 30% of patients have achieved an AHI <5 in medical or surgical weight loss trials. 33 Positional therapy involves use of a positioning device to maintain a position other than supine during sleep, as supine positioning is associated with greater reductions in airway dimensions. 38 The role of positional therapy is predominantly secondary, but it can be used as a supplemental primary therapy in patients demonstrated as having a low-AHI when in a nonsupine position. 39 It is estimated that >50% of all patients with an AHI >5 events/h have a positional component to their sleep apnea. 40 Oral appliances, such as a mandibular advancement device and tongue-retaining devices, work by mechanically enlarging the upper airway by displacing the tongue forward and 41, 43 Baseline AHI ≥30 and maximum therapeutic CPAP pressure >12 mm Hg are predictive of oral appliance treatment failure (success defined by achieving either AHI <5, or 5≤ AHI <10 with >50% reduction from baseline), and thus these clinical features should be considered when selecting patients for oral appliance therapy. 44 Oral appliances are recommended for treatment of primary snoring without OSA, and in mild-to-moderate OSA in cases where the patient strongly prefers to try an appliance over PAP therapy. They are also preferable compared with no therapy for primary snoring without OSA, or OSA of any severity in patients who are intolerant to or unwilling to try PAP therapy. 43 Upper airway surgery is designed to address anatomic airway obstruction in the upper airway and consists of a variety of different techniques. Individual surgical procedures may be classified as nasal, upper pharyngeal, lower pharyngeal, or global upper airway depending on the anatomic level at which obstruction is targeted. Many patients have obstructive anatomy at multiple sites and require multilevel surgical correction, in which several procedures are performed either simultaneously or in a staged manner. Surgery can be considered as primary therapy for patients with primary snoring with OSA, in patients with mild-to-moderate OSA where they may supersede oral appliances, and in cases of obstructive anatomy where surgery would be considered highly effective, and as secondary therapy for patients with OSA who experience inadequate response to or cannot tolerate PAP therapy. 39 Surgery is an effective management option for the treatment of OSA, with reported polysomnographic success rates (generally defined as a ≥50% reduction in AHI to an AHI value ≤20) of 35% to 83% in the literature. [45] [46] [47] [48] [49] Limitations of the reported efficacy in the literature include significant heterogeneity of surgical technique as well as patient selection based on individual anatomic characteristics and surgeon preference. An overview of the different types of surgical procedures used to treat OSA along with reported efficacy of each technique is presented in 60 While the magnitude of this reduction was relatively modest, it has been shown that even small reductions in blood pressure confer reduced risk of adverse cardiovascular events. 61 Based on these data, we believe that diagnostic testing is reasonable in all patients with resistant hypertension, including those without clear signs or symptoms of OSA.
Pulmonary Hypertension
OSA is strongly associated with pulmonary hypertension (PH) and may play a causative role in its pathophysiology. Whereas %10% to 20% of patients with moderate-to-severe OSA have coexisting PH, 62 the prevalence of OSA in patients with PH diagnosed by right heart catheterization has been estimated to be 70% to 80%. 63 Both hypercapnia and nocturnal episodes of hypoxia can trigger pulmonary arteriolar constriction leading to acute, reversible elevation in pulmonary artery pressures. Signaling pathways implicated in hypoxic vasoconstriction in PH include nitric oxide, endothelin, angiopoietin-1, serotonin, and NADPH-oxidase. 64 Chronic hypoxia activates additional inflammatory pathways resulting in pulmonary vascular remodeling and, eventually, irreversible increases in pulmonary vascular resistance. 65 Additional postulated mechanisms contributing to PH include increased right-sided preload resulting from negative transthoracic pressure during periods of airway obstruction, generation of reactive oxygen species as well as endothelial dysfunction within the pulmonary vasculature. 66 Echocardiographic evidence of right ventricular remodeling and dysfunction has been observed in association with OSA as well. 67 In addition to direct mechanisms involving the pulmonary vasculature, OSA can lead to PH indirectly via contributing to left HF with associated postcapillary PH such as in patients with refractory hypertension.
Pulmonary hypertension resulting solely from OSA is generally mild; however, OSA can further exacerbate elevations in pulmonary artery pressures and pulmonary vascular resistance when superimposed on PH associated with other underlying causes. Importantly, the presence of OSA in patients found to have severe PH has been associated with increased mortality. 68 Regarding the effects of OSA treatment in patients with PH, the current literature, while limited by small sample size and paucity of randomized trials, does suggest a benefit. Observational studies have demonstrated reduction in pulmonary vascular resistance in patients treated with CPAP. 69 In the 1 randomized trial to date, treatment of OSA with CPAP was associated with a significant reduction in pulmonary artery systolic pressure (28.9 mm Hg versus 24 mm Hg) when compared with a sham device. 70 Given the detrimental effects of sleep apnea in patients with PH and limited evidence suggesting a beneficial effect of CPAP, we recommend clinical screening of all PH patients for sleep apnea with a comprehensive sleep assessment. In addition, we believe that performing some form of diagnostic sleep testing in all patients with PH is reasonable. We generally perform overnight oximetry testing in patients felt to be at low 75 suggesting the potential of HSAT for a role in evaluating patients at risk for complicated SDB in the future pending further investigation. Sleep apnea is prevalent in patients with asymptomatic left ventricular dysfunction as well as those with clinically overt HF, with 1 study diagnosing moderate-to-severe sleep apnea in 66% of patients with the former. 76 Coexisting sleep apnea has been associated with increased risk of adverse outcomes, including mortality, in patients with HF. 77, 78 Several pathophysiologic processes that result directly from apneic events may explain this association, including activation of the sympathetic nervous system 79 as well as increased preload and afterload resulting from perturbation of intrathoracic pressure while attempting to inspire against occluded airways. 80 Additional mechanisms by which sleep apnea may worsen outcomes in patients with HF include exacerbating systemic hypertension, 81 increased risk of arrhythmias including sudden cardiac death, 82 and an elevated risk of coronary events. 83 Studies investigating the potential benefits of PAP therapy with respect to underlying heart failure in this patient population have been conflicting and ultimately disappointing. Several studies looking at surrogate end points suggested beneficial effects associated with PAP therapy in sleep apnea patients with HF. Reductions in sympathetic nervous system signaling have been observed in patients with both OSA and CSA treated with CPAP. 84 These promising early studies prompted larger RCT looking at hard clinical end points, particularly in patients with predominant CSA. The CANPAP (Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure) trial investigated the effect of CPAP treatment in patients with HF and CSA. No benefit was seen in the patients treated with CPAP; however, a post hoc analysis suggested a reduction in mortality among patients for whom CPAP therapy resulted in a significant improvement in AHI (to <15 events/h). 91 While CPAP is effective in relieving obstructive events, many patients with HF have persistent central apneas and hypopneas despite therapy with appropriately titrated CPAP. Adaptive servoventilation (ASV) is a form of bi-level positive airway pressure therapy in which the degree of pressure support (difference between inspiratory and expiratory pressures) varies between respiratory cycles in order to maintain stable minute ventilation. A backup rate is programmed to trigger breaths during periods of central apnea. This mode therefore offers a theoretic advantage in HF patients with Cheyne-Stokes breathing, which is characterized by periods of hyperventilation, hypoventilation, and central apnea. 92 The SAVIOR-C (Study of the Effects of Adaptive Servoventilation Therapy on Cardiac Function and Remodeling in Patients with Chronic Heart Failure) trial failed to show an improvement in ejection fraction or brain natriuretic peptide (BNP) level after 24 weeks of ASV therapy in patients with HF and CSA but did reveal improvements in quality of life and clinical status. 93 The SERVE-HF (Treatment of Sleep-Disordered Breathing with Predominant Central Sleep Apnea by Adaptive Servo Ventilation in Patients with Heart Failure) trial was designed to test the effect of ASV on mortality in patients with left ventricular ejection fraction ≤45% and predominantly central sleep apnea. Despite effectively reducing the AHI, ASV failed to confer a survival benefit, and actually was associated with an increase in cardiovascular mortality (29.9% versus 24%). 94 Postulated mechanisms for this finding include reductions in cardiac output related to the higher levels of PAP delivered in ASV mode, as well as the hypothesis that CSA is actually a compensatory mechanism in patients with severe HF with beneficial properties that were attenuated by ASV treatment. Additionally, the proprietary algorithm used in SERVE-HF has been shown to induce episodes of significant hyperventilation in some patients, which some suspect may have been related to the increase in mortality. 95 The question of whether SERVE-HF's findings represent a class effect of ASV versus that of 1 specific algorithm may be answered by the ongoing ADVENT-HF (Effect of Adaptive Servo Ventilation on Survival and Hospital Admissions in Heart Failure) trial, which is investigating the effect of ASV therapy on mortality and morbidity in HF patients (left ventricular ejection fraction ≤45%) with SDB using an updated algorithm. 96 Given these results, treatment of ASV is contraindicated in patients with HF and CSA. In contrast to CSA, large randomized trials looking at the effect of CPAP therapy on hard end points in HF patients with predominantly obstructive sleep apnea are lacking. Given the beneficial effect of CPAP on surrogate end points discussed above, in context of the observed increase in adverse events including mortality associated with OSA as well as the absence of studies suggesting harm, we suggest diagnostic testing in HF patients with suspected sleep apnea based on nocturnal symptoms and/or risk factors discovered during a comprehensive sleep assessment.
Atrial Fibrillation
Similar to OSA, AF is common in the general population, with a prevalence of 1% to 2%. 97 In patients with OSA, the prevalence of AF is %5%, 98 while notably the prevalence of OSA in patients diagnosed with AF has been reported as high as 32% to 39%. [99] [100] [101] A significant independent association between the 2 disorders exists even after controlling for confounding conditions such as systemic hypertension, obesity, and HF. 101 While multiple mechanisms have been postulated to explain this association, the most important appear to be nocturnal surges in sympathetic tone, systemic hypertension, and structural remodeling, particularly of the atria. Alterations in both sympathetic and parasympathetic system regulation have been observed in association with OSA. 79 During an apneic episode, vagal efferent output is enhanced, causing transient bradycardia as well as shortened atrial effective refractory period with resultant susceptibility to excitatory stimuli, an effect that can be reversed with atropine or vagotomy. In animal models of OSA, episodic hypoxemia results in surges of sympathetic nervous system output as well as activation of the renin-angiotensin system, reducing the threshold for AF induction. 102 The observation that renal denervation and sympathetic ganglion block provide significant but incomplete protection against apnea-associated AF induction suggests that additional mechanisms beyond neurohormonal activation are relevant. [103] [104] [105] Over time, OSA promotes structural remodeling of both the ventricles and atria, providing an additional pro-arrhythmic mechanism. Exaggerated swings in intrathoracic pressure, as are seen during apneic events, have been shown to cause acute atrial dilation as well as increased frequency of premature beats even in healthy subjects. 109 Significant slowing of atrial conduction also occurs during hypercapnia, even in the absence of hypoxia.
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The susceptibility to AF among patients with OSA likely reflects the combined effects of these various mechanisms, with neurohormonal activation and hypercapnia triggered by acute apneic events superimposed on the vulnerable substrate of a remodeled heart. Beyond the apparent epidemiologic association between the 2 conditions, there is a growing body of evidence to suggest a significant role of OSA in recurrent and/or treatment-refractory AF. In the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation), which included >10 000 patients with AF, those with coexisting OSA had significantly worse AF symptoms and were more likely to be on rhythm control therapy. 87 An increased risk of recurrent AF following an incident episode 88 and worse outcomes after catheter ablation [112] [113] [114] have been observed in patients with OSA. Importantly, there is evidence that treatment of OSA may modify these risks. In the ORBIT-AF cohort, OSA patients treated with CPAP were significantly less likely to progress to permanent AF as compared with OSA patients not receiving CPAP. 87 Furthermore, multiple observational studies have demonstrated a significant reduction in the risk of recurrent AF following catheter ablation among OSA patients treated with CPAP as compared with OSA patients not receiving treatment. 112, [115] [116] [117] A meta-analysis of these studies found that in OSA patients treated with CPAP, the AF recurrence risk following catheter ablation was not significantly different from a control population without OSA, whereas OSA patients not treated with CPAP had a statistically significant 57% increased risk of recurrence (P<0.001). 113 Important limitations of these studies include observational design, diagnosis of sleep apnea via clinical history and/or standardized questionnaires in lieu of formal sleep testing in the majority of cases, and determination of CPAP use via self-reporting. Overall, the current body of literature in this area suggests a possible benefit of treating OSA with CPAP with respect to AF burden and risk of recurrence during rhythm control, particularly following catheter ablation. On the basis of these data, we suggest diagnostic testing with either HSAT or polysomnography in patients with suspected sleep apnea following comprehensive sleep assessment based on nocturnal symptoms and/or risk factors when catheter ablation is planned. This recommendation is consistent with the 2017 Heart Rhythm Society Expert Consensus Statement on catheter and surgical ablation of AF. 118 Furthermore, we believe it is reasonable for clinicians to consider diagnostic testing in select patients with suspected sleep apnea managed via rhythm control strategies other than ablation, although there is currently insufficient evidence to provide specific clinical criteria guiding selection from within this large and heterogeneous group of patients. Providers must therefore apply individualized clinical judgment in selecting patients for HSAT or polysomnography testing, keeping in mind that patients with higher-risk features (history of recurrent AF after cardioversion, anti-arrhythmic drug failure, etc) are more likely to benefit from detection and treatment of OSA. Patients with AF found to have symptoms of SDB and at risk for moderate-to-severe OSA during comprehensive sleep assessment should be referred for diagnostic testing, similar to patients without comorbid AF.
Other Arrhythmias
Beyond AF, OSA has been linked with a spectrum of other cardiac rhythm disturbances as well as sudden cardiac death.
Simantirakis et al reported a 22% prevalence of prolonged pauses and bradycardia in patients with moderate-to-severe OSA who received long-term monitoring with an implanted loop recorder. 119 Patients are considered to have the "tachybrady syndrome" when such bradyarrhythmias alternate with AF or other forms of supraventricular tachycardia. The risk of ventricular arrhythmias also appears to be higher among patients with OSA. Mehra et al found a significantly higher prevalence of nonsustained ventricular tachycardia (5.3% versus 1.2%, P=0.004) among patients with severe OSA compared with controls. 98 Similarly, severe OSA was associated with a significantly higher overall risk of complex ventricular ectopy, defined as nonsustained ventricular tachycardia, bigeminy, trigeminy, or quadrigeminy (25% versus 14.5%, P=0.002). Importantly, an increased risk of sudden cardiac death has been reported in patients with severe OSA, particularly among those observed to have nocturnal oxygen desaturation to <78%. 120 There are limited data suggesting a beneficial effect of CPAP therapy on reducing rhythm disturbances in patients with OSA 119, 121, 122 ; however, additional study is necessary given the small size and predominantly observational nature of these trials.
Coronary Artery Disease, Cerebrovascular Disease, or Patients Without Established CVD Who Are at High Risk for Future Adverse Cardiovascular Events
Associations have been identified between OSA and other forms of CVD in addition to those described above, in particular coronary artery disease (CAD) 58, 123 and cerebrovascular disease. 124 Among the pathophysiologic mechanisms linking OSA with CAD and cerebrovascular disease are some of those described above as involved in other forms of CVD, including increased sympathetic nervous system activity, oxidative stress, and predilection to poorly controlled and/or resistant hypertension. Additional mechanisms have been identified as well, including endothelial dysfunction, 125, 126 promotion of a procoagulable state, 127 and metabolic dysregulation characterized by insulin resistance. 128, 129 Treatment of OSA with CPAP has been shown to mitigate these processes, 127,130,131 offering a plausible mechanism by which treating OSA could influence cardiovascular outcomes. Support for efficacy of OSA treatment on improving cardiovascular outcomes came from early observational studies. A prospective analysis of 54 patients with known CAD and OSA found a significant reduction in the composite end point of cardiovascular death, acute coronary syndrome, hospitalization for HF, or need for coronary revascularization (hazard ratio 0.24; 95% CI, 0.09-0.62; P<0.01) among patients treated for OSA with either CPAP or upper airway surgery; however, these results may have been subject to significant bias because the untreated arm consisted of patients who had refused treatment despite a recommendation from their provider. 132 An observational study that followed 223 patients for 5 years after a stroke found an increased risk of mortality in patients unable to tolerate CPAP versus those who tolerated CPAP (hazard ratio 1.58; 95% CI, 1.01-2.49; P=0.04).
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Similarly, a 444 patient cohort that included patients treated with CPAP, weight loss, or surgery found a significant reduction in mortality associated with each individual treatment modality as compared with untreated patients. When compared with the general population using census-derived survival data, untreated patients had a significantly higher mortality rate, whereas mortality did not differ significantly between the treated patients and general population. 134 Disappointingly though, no randomized trials investigating the impact of PAP therapy on cardiovascular outcomes have shown a clear benefit with respect to hard cardiovascular outcomes. In patients with a history of stroke, Hsu et al found no reduction in recurrent cerebrovascular events in patients with OSA treated with PAP therapy. 135 Peker et al randomized 244 nonsleepy patients with CAD following revascularization and moderate-to-severe OSA to APAP versus no PAP therapy and found no difference in the composite cardiovascular event outcome after a median of 57 months follow-up. 136 The SAVE (Sleep Apnea Cardiovascular Endpoints) trial was the largest RCT designed to investigate the question of whether treating OSA with CPAP may improve cardiovascular outcomes in patients with established CVD.
5 SAVE randomized 2717 patients with moderate-to-severe OSA and either CAD or cerebrovascular disease to CPAP plus usual care or usual care alone and followed them for a mean period of 3.7 years. The trial failed to demonstrate a significant reduction in the primary end point (a composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, HF, or transient ischemic attack) among patients treated with CPAP in addition to usual care (hazard ratio 1.10; 95% CI, 0.91-1.32; P=0.34). Among secondary end points, CPAP was associated with significant reductions in snoring and daytime sleepiness, improvement in healthrelated quality of life and mood, and fewer days off work because of poor health. While these studies included patients with established CVD, the role of PAP therapy for primary prevention in OSA patients without established CVD has also been queried. Barb e et al enrolled 725 nonsleepy patients with moderate-tosevere OSA but no prior history of CVD and randomized them to CPAP versus no therapy. After a median of 4 years, there was no difference in the incidence of systemic hypertension or cardiovascular events including cardiovascular death, nonfatal MI or stroke, TIA, or HF. 137 A 2017 meta-analysis of 10 RCTs (of which 6 required established CVD for enrollment) by Yu et al showed no association between PAP therapy and major cardiovascular events (hazard ratio 0.77; 95% CI, 0.53-1.13; P=0.19).
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While PAP therapy appears to be effective in reducing symptoms of OSA, the results of these randomized trials do not support its efficacy in reducing the risk of adverse cardiovascular events in patients with OSA. Several potential limitations to the available evidence have been cited. 6 First, suboptimal PAP adherence was common, with a median duration of <4 hours/night reported in 6 of the 10 RCTs included in the meta-analysis. 138 In SAVE, by far the largest of all these trials, the median duration of PAP use was 3.3 hours per night, and fewer than half (42%) of those in the CPAP arm achieved "good adherence," defined as ≥4 hours of CPAP use per night. 5 Yu's meta-analysis revealed that in the 4 RCTs achieving median adherence >4 hours/night, PAP therapy was associated with a significantly lower risk of adverse cardiovascular events (relative risk 0.58; 95% CI, 0.34-0.99); however, the implication of this finding is uncertain given the absence of a similar association on a subgroup analysis of patients from all 10 RCTs with good PAP adherence using meta-regression, possible confounding because of nonrandomized differences between adherent and nonadherent patients, and the inherent limitations of post-hoc, subgroup analysis findings. Secondly, patients with severe sleep apnea symptoms (commonly defined by Epworth Sleepiness Scale (ESS) >10) were excluded from several of the randomized trials, and some authors have hypothesized that benefits of PAP therapy on preventing adverse cardiovascular outcomes may be limited to these higher-risk patients with severe OSA. Third, all patients enrolled in the SAVE trial were diagnosed with OSA using HSAT, despite guidelines recommending polysomnography to be used for patients with established significant cardiopulmonary disease, which was one of the inclusion criteria for entry into this study. Therefore, there is the possibility that a significant percentage of the enrolled population may have been affected by Cheyne-Stokes breathing or other forms of mixed apneas that would not have experienced the same benefit from PAP therapy as in patients with strictly obstructive apneas.
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Although these limitations may serve as topics of interest for future investigations, the best available evidence does not support the use of PAP therapy specifically for the purpose of reducing the risk of future adverse events at this time. Therefore, we suggest diagnostic testing for patients with established CAD, cerebrovascular disease, or elevated cardiovascular risk in whom sleep apnea is clinically suspected because of signs or symptoms uncovered during clinical sleep assessment.
Perioperative Risk
Comorbid OSA is relevant to the perioperative management of patients with CVD planning to undergo surgery. OSA not only increases the risk of respiratory complications, but some studies have reported an increased risk of postoperative AF and other cardiac complications. 53 The high prevalence of undiagnosed OSA combined with the observation that perioperative complications are more common in patients with undiagnosed OSA 139 has prompted many centers to incorporate screening for OSA as a routine component of preoperative assessment. Various sleep questionnaires have been utilized in this role, with STOP-BANG being the most validated in the surgical patient population. A STOP-BANG score ≥3 identifies patients at risk of OSA and has been independently associated with an increased risk of perioperative complications. 54 In patients with previously diagnosed OSA, preoperative evaluation should include a review of prior sleep study results to confirm the type and severity of sleep apnea as well as assessment of their compliance with PAP and/or other therapies. Identifying patients with an established diagnosis or high risk for OSA during preoperative assessment provides an opportunity for targeted interventions that may reduce the risk of perioperative cardiopulmonary complications. Specific management issues that warrant consideration include determining the need for additional preoperative cardiopulmonary evaluation and optimization, selection of an appropriate anesthetic strategy, the intensity and duration of postoperative monitoring, and the provision of PAP therapy postoperatively. The 2016 Society of Anesthesia and Sleep Medicine Guidelines on Preoperative Screening and Assessment of Adult Patients with Obstructive Sleep Apnea offers guidance with respect to these questions. 53 A preoperative assessment algorithm reflecting these guidelines is displayed in Figure 1 . ii. We suggest diagnostic testing for patients with established or at risk for CVD in whom sleep apnea is suspected following a comprehensive sleep assessment:
Summary of Proposed Recommendations
1. Symptomatic HF (New York Heart Association Class II-IV) or asymptomatic (New York Heart Association Class I) left ventricular dysfunction (ejection fraction <40%). 2. AF, particularly in patients who are persistently symptomatic, challenging to pharmacologically rate control, or in whom a rhythm control strategy will be pursued. a. Those with a negative or inconclusive HSAT should undergo polysomnography. b. For those with a high pretest probability and negative polysomnography, a repeat polysomnography may be considered. 
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